Screener
Whitehawk Therapeutics WHWK Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Whitehawk Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Whitehawk Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212075
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income (expense), net | 1,328 | 88,234 |
| Loss (income) before income tax expense | (22,194) | 73,016 |
| Income tax expense (benefit) | — | — |
| Net (loss) income | $(22,194) | $73,016 |
| Other comprehensive loss: | ||
| Unrealized loss on investments, net of tax | (135) | (15) |
| Comprehensive (loss) income | (22,329) | 73,001 |
| Net (loss) income per share: |
Item 1. Financial Statements.
FAQ
- What is Whitehawk Therapeutics's net income?
- Whitehawk Therapeutics (WHWK) reported net income of -$22.19M in Q1 2026.
- How has Whitehawk Therapeutics's net income changed year-over-year?
- Whitehawk Therapeutics's net income decreased by 130.4% year-over-year, from $73.02M to -$22.19M.
- What is the long-term trend for Whitehawk Therapeutics's net income?
- Over 3 years (2021 to 2025), Whitehawk Therapeutics's net income has grown at a -42.8% compound annual growth rate (CAGR), from -$110.09M to -$20.6M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Whitehawk Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude